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The availability of a genetic model organism with which to study key molecular events underlying 
amyloidogenesis is crucial for elucidating the mechanism of the disease and the exploration of new 
therapeutic avenues. The natural human variant of β2-microglobulin (D76N β2-m) is associated with a 
fatal familial form of systemic amyloidosis. Hitherto, no animal model has been available for studying in 
vivo the pathogenicity of this protein. We have established a transgenic C. elegans line, expressing the 
human D76N β2-m variant. Using the INVertebrate Automated Phenotyping Platform (INVAPP) and the 
algorithm Paragon, we were able to detect growth and motility impairment in D76N β2-m expressing 
worms. We also demonstrated the specificity of the β2-m variant in determining the pathological 
phenotype by rescuing the wild type phenotype when β2-m expression was inhibited by RNA 
interference (RNAi). Using this model, we have confirmed the efficacy of doxycycline, an inhibitor of 
the aggregation of amyloidogenic proteins, in rescuing the phenotype. In future, this C. elegans model, 
in conjunction with the INVAPP/Paragon system, offers the prospect of high-throughput chemical 
screening in the search for new drug candidates.
β2-microglobulin is a protein composed of 99 amino acids with a characteristic β-sandwich immunoglobulin 
fold. It serves as the light chain of the class I major histocompatibility complex. Amyloid formation by wild-type 
β2-m occurs as a severe complication of long-term dialysis for patients with end-stage kidney failure, as a result 
of the persistently high plasma concentration of β2-m1. So far, only one genetic form of β2-m related amyloido-
sis has been described and this is caused by the mutation Asp76Asn. The clinical and experimental work car-
ried out on this variant has advanced our current understanding of amyloidogenesis of β2-m and other globular 
proteins, including the role of biomechanical forces in protein misfolding2 as well as the mechanism of β2-m 
fibrillogenesis1,3.
Whereas the mechanism of misfolding and aggregation in vitro has been extensively clarified, the mechanism 
of toxicity of amyloid in general and of β2-m in particular remains an unmet challenge. Animal models offer 
important insights on the identification of the protein species causing the tissue toxicity. However, attempts to 
generate animal models for β2-m associated diseases have stalled as, in spite of good levels of expression of β2-m 
in transgenic mice expressing the wild type4 protein or the pathogenic variant D76N, no pathological phenotype 
of β2-m amyloidosis has been observed.
The nematode genetic model organism Caenorhabditis elegans (C. elegans) offers the prospect of stud-
ying the effects of the β2-m variant in vivo. C. elegans models have already been successfully deployed to 
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characterize important molecular aspects of other protein aggregation diseases such as Alzheimer’s, Parkinson’s 
and Huntington’s diseases5–9. C. elegans has several advantages. It shares many characteristics with mamma-
lian systems with respect to genetics, biochemical and physiological functions. It is small, transparent and a 
self-fertilizing hermaphrodite producing 300 identical progeny in 3 days; its life cycle is short (2–3 weeks) and it 
is easy and inexpensive to maintain in the laboratory10. Moreover, chemical and genetic screenings in C. elegans 
are becoming an established method to search for new therapeutic tools and to uncover and validate drug tar-
gets11. We have previously described the phenotypes of transgenic worm strains transiently expressing wild type 
β2-microglobulin and some isoforms not related to the familial form of the disease12. As evidence of the reliability 
of the C. elegans model, we observed that the severity of proteotoxicity in vivo correlated well with the protein’s 
amyloidogenic propensity measured in vitro.
In this paper, we characterize a new transgenic C. elegans strain, named CPV27, expressing the D76N variant, 
in which the β2-m gene is integrated into the C. elegans genome. The development of this new strain was challeng-
ing, due to the high toxicity of the expressed protein at the embryonic stage of development. We have therefore 
prepared a strain in which the expression of the disease-causing variant is under temperature-dependent control, 
using the well-characterized mRNA-surveillance system of C. elegans13. This new worm strain is the first robust 
animal model for studying in vivo the effects of the pathogenic variant of D76N β2-m and represents a valuable 
new tool with which to explore further the disease mechanism and search for new drug candidates to combat 
β2-m amyloidogenesis.
Results
Expression of the D76N β2-m variant. We previously reported a C. elegans model of wild type β2-m 
amyloidosis in which the protein was expressed in the body-wall muscles under the control of the promoter of 
the myosin gene unc-5412. However, our attempts to express the D76N β2-m variant in C. elegans under the same 
promoter failed because the nematodes died before reaching the first larval stage, likely due to the high toxicity 
of the protein variant (data not shown). To bypass the lethal effect of such constitutive protein expression, we 
adopted the well-characterized smg inducible system13. In this protocol, at the permissive temperature of 16 °C, 
the mRNA of the transgene is readily degraded, whereas an upshift to a non-permissive temperature that is still 
compatible with the normal growth of the worms (23–25 °C) (Fig. 1a), inactivates the surveillance machinery 
allowing stabilization and translation of the transgene mRNA. The smg system enabled us to switch-on the expres-
sion of D76N β2-m at the first larval stage (L1), thereby avoiding protein synthesis and its related toxic effects in 
the embryonic stage.
Figure 1. D76N β2-m C. elegans strain genotype characterization and β2-microglobulin expression.  
(a) Scheme of C. elegans manipulation highlighting the stage in which the β2-m expression is activated by 
temperature switch. Eggs were maintained at 16 °C and L1 larvae were up-shifted to 23–25 °C in order to 
induce the expression of the protein. (b) PCR genotyping of adult transgenic nematodes. The expected size of 
PCR products (about 800 bp) was observed after DNA electrophoresis on 1.5% agarose gel (lane 1: EZ Load 
Precision, BioRad, lane 2,4: pcr products of DNA extracted from smg-1 (cc546) ancestral strain, lane 3,5: pcr 
products of DNA extracted from D76N β2-m worms. (c) Representative western blot of β2-m expression. Equal 
amounts of protein (10 μg) were loaded for each sample from smg-1 (-ctrl) or D76N β2-m expressing nematodes 
and immunoblotted with polyclonal anti-human β2-m antibody (Dako) and anti-GAPDH antibody used as 
loading control (M = Molecular weight standard: Precision Plus Western C, BioRad). Uncropped scans of 
immunoblots are shown in Supplementary Fig. S1.
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Transgenic C. elegans were engineered to express D76N β2-m in bodywall muscles under the promoter of 
another myosin gene, myo-3. As the amyloid is an extracellular protein deposit, we sought to obtain protein secre-
tion by replacing the previously used human β2-m signal peptide12 with the signal peptide of the endogenous sel-1 
protein14. We have used, as a co-injection marker, the podr-1::rfp plasmid, which shows a strong pattern of red 
fluorescent protein (RFP) expression (RFP expressed in two head neurons, AWB and AWC). After engineering 
the D76N β2-m expressing plasmid, microinjection into the gonad and integration of the transgene by UV irradi-
ation, the exact genotype of D76N β2-m expressing nematodes was confirmed by single worm PCR (Fig. 1b, lane 
3,5) and DNA sequence analysis.
The strain obtained after integration smg-1(cc546); pavIs1[pmyo-3::SPsel-1::hD76Nβ2-m::Smg sensitive 3′UTR; 
podr-1::rfp], named CPV27, correctly expressed D76N β2-m, as shown by western blot analysis (Fig. 1), when 
animals were grown at 25 °C beginning at the L1 larval stage. Levels of protein increased from the first to the fifth 
day when nematodes were grown at 25 °C (Fig. 1c). D76N β2-m nematodes, maintained at 16 °C and collected 24 h 
after the L4 stage, were also analyzed. The absence of expression of β2-m at 16 °C confirmed the efficiency and the 
specificity of the thermo-inducible system, therefore the smg-1(cc546) ancestral strain (PD8120 strain) served as 
a negative control (Fig. 1c).
Aggregation state of the β2-m variant. A search of amyloid deposits was carried out by microscopic 
analysis of worms stained with the amyloid probe NIAD-4 as previously described15. However, we did not detect 
amyloid material at any stage of development (data not shown). In spite of a lack of clearly visible amyloid depos-
its, the β2-m variant in worms displayed a high propensity to form soluble self-assemblies as shown by both 
electrophoresis and size exclusion chromatography (Fig. 2). Worms were lysed and after centrifugation, both 
supernatant and pellet were first analysed by SDS-PAGE and β2-m detected by immunoblotting. As clearly shown 
in Fig. 2a, almost all the β2-m present is recovered in the supernatant and not in the pellet obtained from the 
worm lysate.
Figure 2. Self-assembly of β2-m D76N in transgenic C. elegans strain. (a) Immunoblot analysis of soluble (SF) 
and insoluble fraction (IF) of worm lysates grown at 25 °C resolved via 8–18% SDS PAGE and detected with 
anti-β2-m antibody (DAKO). The insoluble fraction was washed twice in PBS buffer before loading onto gel. 
(M = Molecular weight standard: Precision Plus Western C, BioRad). (b–d) Size-excluded soluble proteins 
from β2-m expressing nematodes and recombinant D76N β2-m. Shown is the absorbance at 280 nm (Abs 
280) of eluted material against elution volume. Fractions (1 ml) were collected. (c–e) Immunoblot analysis of 
size-excluded fractions (6–20) of β2-m expressing worms’ lysates and recombinant β2-m resolved via 8–18% 
SDS PAGE and detected with anti-β2-m antibody (DAKO). Uncropped scans of immunoblots are shown in 
Supplementary Fig. S2a.
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Chromatographic analysis carried out on the supernatant in physiological buffer reveals that β2-m is eluted 
in a wide range of molecular weights, from the most abundant 11 kDa of the monomeric state (fractions 14–16, 
Fig. 2b,c) to heterogeneous oligomeric states up to and beyond 100 kDa (fractions 8–9, Fig. 2b,c). Such heter-
ogeneous states of aggregation are not present when recombinant β2-m was loaded at different concentrations 
(Fig. 2a) and this finding is confirmed when the soluble fraction of recombinant β2-m is analysed by size exclusion 
chromatography (Fig. 2d,e). The smg-1 mutant worms were analysed as well and used as negative controls in order 
to exclude any possible cross-reaction of the antibody (S2b).
Our hypothesis, which has been confirmed by the experiments on the characterization of CPV27 transgenic 
strain reported below, was that the expression and accumulation of monomeric and oligomeric species of D76N 
β2-m variant correlate with a pathological phenotype in our C. elegans strain.
Effects of β2-m expression on the C. elegans phenotype. INVAPP/Paragon analysis of worms’ growth 
and motility. To investigate the effect of expressing D76N β2-m on nematode growth and motility, an auto-
mated analysis was carried out using the recently developed INVAPP/Paragon system16. Briefly, the automated 
platform is able to quantify growth and/or motility of nematodes, by acquiring images of nematode growth 
medium (NGM) plates containing worms and by thresholding pixel variance to determine motion. Quantified 
movement is recorded as a movement index parameter, which increases with the number and size of worms per 
plate, reflecting a larger number of ‘motile’ pixels in the recording. After placing three L4 larvae per plate, we 
followed the growth and motility of their progeny. At day six at 25 °C (Fig. 3a), both the smg-1 controls and D76N 
β2-m expressing worms were imaged with INVAPP/Paragon (Fig. 3b) and their movement index was meas-
ured (Fig. 3c). D76N β2-m expressing worms showed slower growth and reduced overall motility than the smg-1 
control strain. Indeed, the movement index was 53% of the value observed for the smg-1 control strain (Fig. 3c, 
**p < 0.01, t-test). The INVAPP/Paragon platform shows that an abnormal behavioural phenotype is associated 
with the expression of the amyloidogenic protein.
To check whether the phenotype of the D76N β2-m strain correlated with the expression of the D76N variant 
of β2-microglobulin, we silenced the β2-m gene by feeding worms with bacteria that produce dsRNA target-
ing the β2-m transgene. Western blot analysis of worms treated with RNAi bacteria were compared with those 
fed with control bacteria (Fig. 4a,b) showing that the D76N β2-m protein was significantly reduced relative to 
the control (Fig. 4c). Most importantly, the reduction in the levels of β2-m expression correlated with the near 
Figure 3. Movement index analysis using the INVAPP/Paragon system. 3 L4 worms/well were placed onto 
NGM 6-well plates, fed with OP50 E. coli, and maintained at 25 °C for six days (a). Worms were imaged using 
INVAPP Paragon software (b). Data are mean of movement index parameter ± SEM; which was obtained 
after processing the acquired images (c). Three independent experiments were carried out and the results were 
plotted using GraphPad Prism (v6), **p < 0.01 vs the control (smg-1) according to t-test.
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complete abrogation of the D76N β2-m strain pathological phenotype (Fig. 4d, dark grey bar, n = 3, °p < 0.05 vs. 
not silenced D76N β2-m expressing worms, t-test).
The index movement parameter recorded by the INVAPP/Paragon system, combines the contributions of 
different phenotypic features: motility, larval development and size of the progeny.
In order to further dissect the results obtained with INVAPP/Paragon, we have carried out a body bends assay, 
a lifespan measurement and a brood size assay.
Body bends assay. The results of body bends assay at 23 °C are reported in Fig. 5a. At day 1 of adulthood, there is 
no difference between D76N and controls. A statistically significant reduction in the number of body bends per 
minute is observed from the fifth day (about 8% decrease; n = 3, **p < 0.01 at day 5 and *p < 0.05 at day 6 when 
compared to corresponding smg-1 controls, one-way ANOVA, N = 40 animals for each group). The body bends 
assay shows that the phenotypic abnormality of D76N β2-m expressing worms, quantified using the INVAPP/
Paragon system, was only partially due to dysfunctions in coordination and motility. For this reason, other phe-
notypic assays were performed.
Lifespan. Measurement of lifespan was performed on synchronized nematodes upshifted to 23 °C from the first 
larval stage. The D76N β2-m strain showed a median survival of 8 days, while that of the smg-1 control strain was 
10 days (Fig. 5b). Apparently, the difference between the two strains is mostly attributable to the first part of the 
Kaplan-Meier graph, and after ten days of adulthood, the two plots become closely aligned. A Peto-Peto-Prentice 
test shows that these differences are significant (χ2 = 5.52, p = 0.019).
Figure 4. D76N β2-m expression is prevented by RNA-interference (RNAi). Equal amounts of proteins (40 µg) 
were loaded on each lane and immunoblotted with polyclonal anti-human β2-m antibody (a) and with anti-
GAPDH (b). Lanes: M = Precision Plus Western C (Bio Rad) molecular weight standard. smg-1 incubated at 
25 °C and collected at day 1 of adulthood. D76N β2-m expressing nematodes incubated at 25 °C and collected at 
day 1 of adulthood and fed with HT115 bacteria transformed, as reported in the Methods section, with PAV2 
plasmid for RNA-interfering (black box) or with control bacteria. Uncropped scans of immunoblots are shown 
in Supplementary Fig. S3. (c) Percentage of β2-m expression is given as D76N β2-m/GAPDH ratio of the WB 
band density of the RNAi strain relative to the control at their first day of adulthood. Density of the bands was 
determined by Image Studio Lite (LI-COR Biosciences). Three independent WB experiments were carried out 
and the results were plotted using GraphPad Prism (v6), p = 0.0052 vs the control level of expression (black) 
according to one sample t-test. (d) Index movement analysis. Three L4 worms were placed into NGM plates, fed 
with HT115/L4440 or HT115 bacteria transformed with PAV2 for RNA interference. Plates were maintained 
at 25 °C for 5 days. At this stage, the plates with adult worms and progenies were analysed by INVAPP Paragon 
software. Three independent experiments were carried out and the results were plotted using GraphPad Prism 
(v6). Data are mean of movement index parameter ± SEM; **p < 0.01 vs ctrl worms and °p < 0.05 vs the non-
silenced D76N β2-m expressing according to one-way Anova.
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Brood size assay. Brood size assay of transgenic animals was then performed by counting the number of eggs 
laid from a single nematode during the first 48 h of adult life at 23 °C (Fig. 5c, n = 3 *p < 0.05 vs smg-1 control 
strain according to t-test). The D76N β2-m expressing animals showed a 17% reduction in brood size compared 
to the smg-1 control strain (Fig. 5c). In addition, the egg viability test was performed, by counting the number of 
unhatched eggs 24 h after their deposition (Fig. 5d, ***p < 0.001 vs. the control strain, t-test). When compared 
to the control strain, egg viability was significantly reduced in the D76N β2-m expressing strain: smg-1 control 
nematodes had less than 10% unhatched progeny, while 35% of the eggs produced by D76N β2-m-expressing 
worms did not hatch (Fig. 5d).
We therefore confirmed that the phenotypic impairment, shown by the movement index parameter, is attrib-
utable to a sum of various contributions: defect in the motility, reduction in the lifespan and fertility and larval 
development impairment of the D76N β2-m expressing strain. No significant difference was detected in D76N 
β2-m expressing adult worms in terms of dimensions in comparison to controls (S4).
Experiments performed on extrachromosomal strains expressing WT and D76N β2-m confirmed the higher 
toxicity of the variant compared to the WT form (S5).
Phenotypic rescue by doxycycline. This novel transgenic C. elegans model was used to investigate the 
phenotypic rescuing capacity of doxycycline, a drug able to inhibit in vitro the fibrillogenesis of D76N β2-m17,18. 
Nematodes treated with 100 μM doxycycline were analysed after 6 days at 25 °C using the INVAPP/Paragon sys-
tem showing that the treatment increased the movement index by two-fold, compared to untreated controls 
(Fig. 6a, ***p < 0.001 vs the untreated control according to one-way Anova). Thus confirming the efficacy of 
this drug in reducing the cytotoxicity of amyloidogenic proteins also in vivo12,17,19. In order to analyze only the 
Figure 5. Characterization of the phenotype of D76N β2-m strain by classic behavioral assays. (a) Egg-
synchronized control worms (smg-1) and D76N β2-m expressing worms were placed at 23 °C into fresh NMG 
plates seeded with OP50 E. coli. At day 1, 5 and 6 of adulthood body bends were scored in liquid. At least three 
independent assays were performed. Data are mean of number of body bends/min ± SEM; **p < 0.01 and 
*p < 0.05 vs the control strain (smg-1), according to one-way ANOVA (N = 40 animals for each group).  
(b) Kaplan–Meier survival curves of control nematodes and D76N β2-m strain. Data are expressed as mean of three  
independent experiments (N = 40 animals for each group, χ2 = 5.52, p = 0.019 according to Peto-Peto-Prentice 
test). (c) Total eggs deposition for smg-1 and D76N β2m strains maintained at 23 °C. At least three independent 
assays were performed. Error bars represent the SEM, *p < 0.05 vs. the control strain (smg-1) according to t-test. 
(d) Percentage of not-hatched eggs of smg-1 and D76N β2-m strains analyzed 24 h after deposition. At least three 
independent assays were performed. Error bars represent the SEM, ***p < 0.001 vs. the control strain according 
to t-test.
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contribution of the drug on movements, we performed a body bends assay on adult worms that were grown in 
presence of 100 μM doxycycline. At day 5 of adulthood, we observed a recovery in the motility of D76N β2-m 
worms treated with this drug compared to controls not treated, indicating that doxycycline also has an effect on 
movement (Fig. 6b, ***p < 0.001 vs the untreated control, according to one-way ANOVA).
To understand the still elusive protective mechanism of doxycycline, we tested in our model the formation of 
oligomers in the presence of the drug. By using size exclusion chromatography followed by western blot analy-
sis, we successfully observed a reduction of the oligomeric β2-m species in nematodes treated with doxycycline 
(Figs. 6c, S6). As shown in Fig. 6c, the fraction of oligomers is considerably reduced in the D76N β2-m worms 
treated with the drug (Fig. 6c, red bars).
conclusions
The smg-system enables the inducible expression of D76N β2-m, thereby circumventing its lethal toxicity in the 
very early stages of C. elegans development. The novel C. elegans’ strain (CPV27) expressing this rare and patho-
genic variant of β2-m represents the first robust animal model for studying the pathogenic conformer of the β2-m 
protein. Although amyloid deposits were not detected, we have shown that the β2-m variant self-aggregates in vivo 
Figure 6. (a) Movement index analysis in presence and absence of doxycycline. Three L4 worms/well were 
placed onto NGM 6-well plates, fed with OP50 E. coli, and incubated at 25 °C for six days in presence of 0 or 
100 μM of doxycycline from the L4 larval stage. Then the plates with adult worms and progenies were analyzed 
by INVAPP Paragon software. Three independent experiments were carried out and the results were plotted 
using GraphPad Prism (v6), ***p < 0.001 vs the untreated control (D76N β2-m expressing nematodes) and 
°p < 0.5 vs. the ctrl worms according to one-way Anova. (b) Egg-synchronized control worms (smg-1) and 
D76N β2-m expressing worms were placed at 23 °C into fresh NMG plates seeded with OP50 E. coli. At day 5 
of adulthood body bends were scored in liquid. At least three independent assays were performed. Data are 
mean of number of body bends/min ± SEM; ***p < 0.001 vs the untreated control (D76N β2-m expressing 
nematodes) and ****p < 0.0001 vs the ctrl worms, according to one-way ANOVA (N = 40 animals for each 
group). (c) Percentage of β2-m in eluted fractions from gel filtration of D76N β2-m expressing worms treated 
with 0 or 100 μM of doxycycline, is given as ratio of D76N β2-m quantity of eluted fraction/soluble fraction 
starting material quantified from WB bands density related to the monomeric molecular weight (mean ± SEM, 
n = 2). Uncropped scans of immunoblots are shown in Supplementary Fig. S6. Density of the bands was 
determined by Image Studio Lite (LI-COR Biosciences).
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generating soluble, high molecular weight, oligomeric species that are responsible for an abnormal phenotype in 
our novel C. elegans strain.
Our attempts to visualize and localize β2-m using anti-β2-m antibody tagged with a fluorescent dye were 
not completely successful (data not shown) but, in order to consider more deeply the pathogenesis of D76N 
β2-m-induced pathological phenotype, it will be important to pursue immunofluorescence studies with improved 
antibodies.
We demonstrated the capacity of doxycycline to rescue the adverse phenotype resulting from D76N β2-m, 
most likely by interfering with the formation of oligomeric conformers in vivo12,17.
The INVAPP/Paragon platform is a useful tool for studying the proteotoxicity of this β2-m variant. In future, 
this platform, which tends itself to high-throughput chemical screening, may expedite the search for new drug 
candidates for the treatment of D76N β2-microglobulin related amyloidosis, an unmet clinical need.
Methods
construction of C. elegans strain and maintenance. Transgenic animals with thermo-inducible 
expression of β2-m based on the well-characterized smg mRNA-surveillance system13 were prepared modifying 
the pPD118.60 plasmid (L3808, a  gift from Andrew Fire, Addgene plasmid #1598; http://n2t.net/addgene:1598; 
RRID:Addgene_1598), which was then injected in PD8120 smg-1(cc546) C. elegans strain, provided by the 
Caenorhabditis Genetics Center (CGC, University of Minnesota, USA). To modify plasmid pPD118.60, oligonu-
cleotides containing compatible sticky ends and encoding the signal peptide of C. elegans sel-1 (Forward oligo: 
5′GCCGCATGATTAAA ACCTATCTGACACTGTTGCTACTAGCAACTCGGCCACGTGTG 3′; Reverse oligo: 
5′CTAGCACACGTGGCCGAGGTTGCTAGTAGCAACAGTGTCAGATAGGTT TTAATCATGC3′) (Primm, 
Milan, Italy) were ligated between the unique NotI and NheI sites in the pPD118.60 plasmid. Amplified cDNA for 
human D76N β2-m was inserted in the engineered plasmid containing sel-1 signal peptide between the unique 
NotI and NheI restriction sites. DNA sequencing was carried out to confirm that the sub-cloned plasmid was 
correct. The plasmid obtained (PAV1) was therefore injected into smg-1(cc546) strain as part of a DNA mix 
containing 30 ng/μl of β2-m construct PAV1 together with 40 ng/μl of plasmid podr-1::rfp as co-injection marker 
(kind gift  of C. Bargmann, Rockfeller University, New York, USA), and extrachromosomal transmitting lines 
were obtained. A strain expressing WT β2-m was also similarly established, inserting amplified cDNA for human 
WT β2-m in the engineered plasmid aforementioned (see S4 for the phenotypic characterization of the strain). 
Completely stable chromosomally integrated lines expressing D76N variant were subsequently derived after UV 
irradiation20, and one clone named CPV27, was chosen for subsequent analysis. After irradiation, CPV27 strain 
was back-crossed with smg-1 ancestral worms in order to remove background mutations arising from the irra-
diation process. Transgenic worms were thus engineered to express human D76N β2-m under the temperature 
inducible control of the body-wall muscle-specific myo-3 promoter.
The smg-1 ancestral strain and D76N β2-m strain were grown in Petri dishes on nematode growth medium 
(NGM) and fed with the OP50 strain of Escherichia coli20. Age synchronized worms were obtained by bleaching 
adult nematodes with alkaline solution (500 mM NaOH, 1.5% NaClO) and eggs were isolated and maintained at 
16 °C. When they reached the L1 larval stage, the expression of D76N β2-m was induced by increasing tempera-
ture to 23 or 25 °C.
Genotype characterization. C. elegans DNA was extracted using lysis buffer for DNA extraction (10 mM 
Tris-HCl pH 8.3, 50 mM KCl, 2.5 mM MgCl2, 0.45% Tween20, 0.45% Triton X-100, 200 μg/ml proteinase K) 
and by incubation for 1 h at 60 °C. To check the presence of the injected plasmid, single worm PCR was car-
ried out using the following primers: L3808ForEst: 5′TGCTATG AAAACGGCACAAA 3′, L3808RevEst: 5′ 
TTCTTCTTCACGTTCCTCACTG 3′. Expected molecular weight of PCR products was verified by DNA elec-
trophoresis on 1.5% agarose gel. After purification of the PCR products with QIAquick PCR Purification Kit 
(Qiagen), DNA sequencing was performed (Eurofins Genomics Italy, Milano).
β2-m expression. Worms were collected at the first or fifth day of adulthood, in M9 buffer (45 mM KH2PO4, 
42 mM Na2HPO4, 85 mM NaCl, 1 mM MgSO4 in water) and lysed by sonication in lysis buffer (25 mM Tris-HCl 
pH 7.5, 5 mM NaCl, 5 mM EDTA, 1 mM DTT, protease inhibitor cocktail Roche Applied Science). For each 
lysate, equal amounts of total proteins, quantified with the Pierce BCA Protein Assay Kit (ThermoScientific), 
were loaded onto either a 4–20% Mini-PROTEAN TGX (Biorad) or 8–18% Excel SDS gel (GE Healthcare) for 
electrophoresis performed under reducing conditions. Proteins were transferred to Immobilon P membranes 
(Millipore) and blocked with 5% non-fat milk, in tris-buffered saline and Tween 20 (TBS-T), for one hour. 
Western blots were developed with 4.6 μg/ml rabbit polyclonal anti-human β2-m antibody (A0072, Dako) O.N. 
at 4 °C and 1.3 ng/ml anti-rabbit IgG peroxidase conjugate (A0545 Sigma) for 1 h RT, as primary and secondary 
antibody respectively. To normalize the content of total protein, western blot was developed with 0.185 μg/ml 
anti-glyceraldehyde 3-phosphate dehydrogenase antibody (anti-GAPDH selected as loading control, ab181602 
Abcam) O.N. at 4 °C, and 1.3 ng/ml secondary anti-rabbit IgG peroxidase conjugate (A0545 Sigma) antibody 
for 1 h RT. Immunoreactive bands were detected by ECL chemio-luminescence (Millipore), and quantified with 
Image Studio Lite (LI-COR Biosciences).
Self-assembly of D76N β2-m in CPV27 C. elegans strain. A pellet containing transgenic C. elegans was 
resuspended in M9 and lysis buffer for further sonication. After centrifugation at 21,000 g for 10 min at 4 °C, the 
soluble fraction was collected and diluted to 1 mg/ml with water. A single 500 μl sample containing 0.5 mg total 
protein was loaded into a Superdex 75 10/300 GL gel filtration column equilibrated and eluted with PBS pH 7.5 
at a flow rate of 0.5 ml/min using an Akta Pure FPLC. Fractions of 1 ml were collected and analysed by 8–18% 
SDS-PAGE and immunoblotted as above.
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Larval growth and motility automated assay (INVAPP/Paragon system). Three synchronized 
nematodes, at their L4 larval stage, were picked onto NGM 6-well plate and incubated at 25 °C. After six days at 
25 °C, plates were imaged using a fast high-resolution camera (Andor Neo, resolution 2560 × 2160, maximum 
frame rate 100 frames/s) with a line-scan lens (Pentax YF3528) as previously described16. Plates were placed in a 
holder built into the cabinet and imaged from below. Movies were captured using μManager and analyzed with 
a set of MATLAB scripts (https://github.com/fpartridge/invappparagon16). Briefly, this involved calculating the 
variance through time for each pixel. Pixels whose variance was above the threshold (typically those greater than 
one standard deviation away from the mean variance) were considered ‘motile’. The ‘motile’ pixels were counted 
and a movement score generated for each well/plate.
Gene silencing by RNA interference (RNAi). The RNAi experiments were performed using a feeding 
procedure21. C. elegans were fed with HT115 (DE3) bacteria expressing dsRNA targeting β2-m. Human β2-m 
cDNA was inserted in the L4440 vector (kind  gift of A.Fire, Stanford University, USA) between KpnI and SacI 
restriction sites to obtain plasmid PAV2. HT115 E. coli bacteria were transformed with PAV2 plasmid and then 
cultured onto LB plates with 100 μg/ml ampicillin and RNAi production was induced by the addition of 1 mM 
IPTG. Control HT115 bacteria were prepared after transformation with the empty L4440 vector. Synchronized 
nematodes at the L4 larval stage were cloned onto NMG plates seeded with RNAi bacteria or the control. Plates 
were imaged after 5 days at 25 °C using the INVAPP/Paragon system and motility scored. Animals were also col-
lected for western blot analysis.
Body bends assay. Body bends assays were performed using a stereomicroscope (M165 FC Leica) equipped 
with a digital camera (Leica DFC425C and SW Kit). Worms at day 1, 5 and 6 of adulthood incubated from L1 
larval stage at 23 °C in presence or absence of 100 µM of doxycycline were picked and transferred into a 96-well 
microtiter plate containing 100 µl of M9 buffer. The number of left-right movements in a minute was recorded. In 
order to remove the progeny, worms were transferred onto fresh NGM plates every day.
Life-span assay. Forty synchronized adult worms maintained at 16 °C were upshifted to 23 °C at the larval 
stage L1. Every day, they were transferred onto a freshly prepared NGM plate until the cessation of egg-laying 
to avoid the overlapping of generations. Viability was monitored until all worms were reported dead when they 
failed to display touch-evoked movement.
Brood size assay and embryonic lethality. Synchronized populations, were grown at 16 °C until their 
first larval stage, and then upshifted to 23 °C. Afterwards L4 transgenic hermaphrodites were individually cloned 
onto agar plates maintained at 23 °C and subsequently transferred onto fresh plates at 8-to-16 hour intervals until 
the second day of adulthood. Then total number of eggs laid in 48 hours was scored and embryos were considered 
dead if they had not hatched after 24 h at 23 °C. The brood size of each animal is the sum of non-hatched and 
hatched progeny. Embryonic lethality is the number of non-hatched embryos divided by the sum of non-hatched 
and hatched progeny.
Doxycycline treatment. Synchronized nematodes at L4 larval stage, incubated at 25 °C from the L1 larval 
stage to allow protein expression, were placed into NGM agar plates seeded with HT115 E. coli resistant to tetra-
cycline and in the presence of 0 or 100 μM of doxycycline. Plates were imaged six days later using the INVAPP/
Paragon system and motility scored. Worms were also collected and lysed in order to perform size-exclusion 
chromatography and western blot analysis as reported before.
Statistical analysis. Data were analysed using independent Student’s t-test or one-way ANOVA test with 
GraphPad Prism 6.0 software (CA, USA). A p value under 0.05 was considered statistically significant.
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